BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/520/0.1/20.09.24

BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/520/0.1/20.09.24 Stock

DE000VD001N2

Real-time Boerse Frankfurt Warrants 07:54:02 2024-06-18 EDT
0.9 ^EUR	-10.00%

Current month	+40.85%
1 month	+112.77%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/520/0.1/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465	06-17	MT
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials	06-14	MT
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress	06-14	BU
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on CASGEVY (Exagamglogene Autotemcel)	06-14	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-18	0.9	-10.00%
24-06-17	1	-17.36%
24-06-14	1.21	+6.14%
24-06-13	1.14	+0.88%
24-06-12	1.13	-16.91%

Real-time Boerse Frankfurt Warrants

Last update June 18, 2024 at 07:54 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Vontobel
WKN	VD001N
ISIN	DE000VD001N2
Date issued	2024-02-26
Strike	520 $
Maturity	2024-09-20 (94 Days)
Parity	10 : 1
Emission price	0.78 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.64 €
Lowest since issue	0.115 €
Spread	0.14 €
Spread %	13.59%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company